Wilson & Boucher Capital Management LLC Sells 200 Shares of Abbott Laboratories (NYSE:ABT)

Wilson & Boucher Capital Management LLC trimmed its stake in shares of Abbott Laboratories (NYSE:ABT) by 1.5% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 13,009 shares of the healthcare product maker’s stock after selling 200 shares during the quarter. Abbott Laboratories accounts for 1.2% of Wilson & Boucher Capital Management LLC’s portfolio, making the stock its 23rd largest holding. Wilson & Boucher Capital Management LLC’s holdings in Abbott Laboratories were worth $1,432,000 as of its most recent SEC filing.

Several other large investors also recently modified their holdings of the stock. Wellington Management Group LLP boosted its holdings in shares of Abbott Laboratories by 4.3% in the 3rd quarter. Wellington Management Group LLP now owns 31,208,711 shares of the healthcare product maker’s stock worth $3,022,564,000 after acquiring an additional 1,298,219 shares in the last quarter. Northern Trust Corp grew its holdings in shares of Abbott Laboratories by 1.5% during the third quarter. Northern Trust Corp now owns 23,016,235 shares of the healthcare product maker’s stock worth $2,229,122,000 after purchasing an additional 343,559 shares during the last quarter. Norges Bank acquired a new stake in shares of Abbott Laboratories in the fourth quarter valued at $2,115,836,000. Charles Schwab Investment Management Inc. lifted its position in Abbott Laboratories by 1.7% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 12,360,908 shares of the healthcare product maker’s stock worth $1,346,959,000 after buying an additional 207,031 shares in the last quarter. Finally, Fisher Asset Management LLC increased its position in Abbott Laboratories by 2.4% in the 4th quarter. Fisher Asset Management LLC now owns 9,930,872 shares of the healthcare product maker’s stock valued at $1,093,091,000 after acquiring an additional 236,741 shares in the last quarter. 75.18% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

A number of brokerages recently commented on ABT. Raymond James reiterated a “buy” rating and issued a $124.00 price objective on shares of Abbott Laboratories in a research report on Wednesday, April 24th. Evercore ISI increased their price objective on shares of Abbott Laboratories from $120.00 to $125.00 and gave the company an “outperform” rating in a report on Thursday, April 4th. Barclays dropped their target price on shares of Abbott Laboratories from $141.00 to $140.00 and set an “overweight” rating for the company in a research report on Monday, April 22nd. Royal Bank of Canada reduced their price target on Abbott Laboratories from $128.00 to $125.00 and set an “outperform” rating on the stock in a research report on Thursday, April 18th. Finally, Citigroup cut their target price on Abbott Laboratories from $128.00 to $119.00 and set a “buy” rating on the stock in a research note on Wednesday. Three research analysts have rated the stock with a hold rating and seven have given a buy rating to the company’s stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $120.60.

Abbott Laboratories Stock Down 0.3 %

Shares of NYSE ABT traded down $0.28 during trading hours on Friday, hitting $103.95. The company had a trading volume of 4,455,866 shares, compared to its average volume of 5,510,455. Abbott Laboratories has a 1-year low of $89.67 and a 1-year high of $121.64. The company has a quick ratio of 1.11, a current ratio of 1.60 and a debt-to-equity ratio of 0.32. The firm’s 50 day moving average is $108.08 and its 200-day moving average is $109.63. The stock has a market capitalization of $180.83 billion, a P/E ratio of 32.38, a price-to-earnings-growth ratio of 2.51 and a beta of 0.76.

Abbott Laboratories (NYSE:ABT) last posted its quarterly earnings results on Wednesday, April 17th. The healthcare product maker reported $0.98 EPS for the quarter, topping analysts’ consensus estimates of $0.96 by $0.02. Abbott Laboratories had a return on equity of 20.18% and a net margin of 13.96%. The business had revenue of $9.96 billion during the quarter, compared to analysts’ expectations of $9.88 billion. During the same quarter last year, the company posted $1.03 earnings per share. Abbott Laboratories’s quarterly revenue was up 2.2% on a year-over-year basis. On average, analysts expect that Abbott Laboratories will post 4.62 earnings per share for the current fiscal year.

Insider Buying and Selling at Abbott Laboratories

In related news, EVP Jr. Robert E. Funck sold 10,097 shares of Abbott Laboratories stock in a transaction that occurred on Friday, May 10th. The stock was sold at an average price of $104.57, for a total transaction of $1,055,843.29. Following the completion of the sale, the executive vice president now directly owns 211,341 shares of the company’s stock, valued at approximately $22,099,928.37. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. In related news, EVP Daniel Gesua Sive Salvadori sold 963 shares of the stock in a transaction that occurred on Friday, March 1st. The stock was sold at an average price of $118.50, for a total transaction of $114,115.50. Following the sale, the executive vice president now owns 125,697 shares of the company’s stock, valued at $14,895,094.50. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, EVP Jr. Robert E. Funck sold 10,097 shares of Abbott Laboratories stock in a transaction on Friday, May 10th. The shares were sold at an average price of $104.57, for a total value of $1,055,843.29. Following the completion of the transaction, the executive vice president now directly owns 211,341 shares of the company’s stock, valued at $22,099,928.37. The disclosure for this sale can be found here. Insiders have sold a total of 34,384 shares of company stock valued at $3,653,916 in the last three months. 1.10% of the stock is currently owned by company insiders.

About Abbott Laboratories

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon.